![Sumanta K. Pal discusses CD70-Targeted Allogeneic CAR T-Cell Therapy for ccRCC – Cancer Discovery](https://oncodaily.com/pub/uploads/2024/06/SmRHi-_U_400x400-1-e1719240309294.png)
Photo from Sumanta K. Pal/X
Jun 30, 2024, 13:42
Sumanta K. Pal discusses CD70-Targeted Allogeneic CAR T-Cell Therapy for ccRCC – Cancer Discovery
Cancer Discovery shared on X:
“Published by a nonprofit professional society, the journal enhances knowledge and supports the cancer research community. Watch Dr. Sumanta K. Pal discuss his research, CD70-Targeted Allogeneic CAR T-Cell Therapy for ccRCC, published concurrently at AACR24.”
![Sumanta K. Pal discusses CD70-Targeted Allogeneic CAR T-Cell Therapy for ccRCC - Cancer Discovery 1 Sumanta K. Pal](https://oncodaily.com/pub/uploads/2024/06/GQxiufjXEAALF8P-800x419.jpeg)
Source: Cancer Discovery/X
Sumanta (Monty) Pal, MD, is a medical oncologist and an expert in genitourinary cancers at the City of Hope Comprehensive Cancer Center in Los Angeles. He serves as the co-director of the Kidney Cancer Program and leads the Kidney and Bladder Cancer Disease Team at City of Hope. He specialises in kidney, bladder, and prostate cancers.
Aug 26, 2024, 06:10